Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Liabilities (2018 - 2025)

Arcturus Therapeutics Holdings' Total Liabilities history spans 8 years, with the latest figure at $57.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 44.55% year-over-year to $57.2 million; the TTM value through Dec 2025 reached $57.2 million, down 44.55%, while the annual FY2025 figure was $57.2 million, 44.55% down from the prior year.
  • Total Liabilities reached $57.2 million in Q4 2025 per ARCT's latest filing, down from $57.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $180.1 million in Q4 2022 to a low of $57.2 million in Q4 2025.
  • Average Total Liabilities over 5 years is $133.4 million, with a median of $144.3 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: skyrocketed 188.08% in 2021, then crashed 46.88% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $164.6 million in 2021, then rose by 9.4% to $180.1 million in 2022, then decreased by 16.21% to $150.9 million in 2023, then crashed by 31.68% to $103.1 million in 2024, then plummeted by 44.55% to $57.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Total Liabilities are $57.2 million (Q4 2025), $57.8 million (Q3 2025), and $78.2 million (Q2 2025).